Faricimab ophthalmic was approved by the FDA on January 28, 2022. This approval covers its use in adults for treating neovascular age-related macular degeneration and diabetic macular edema.
Jul 18th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Daridorexant was approved by the U.S. Food and Drug Administration (FDA) on January 7, 2022, for the treatment of insomnia in adults who have difficulty falling asleep or staying asleep.